March 21, 2023
Brandon BioCatalyst, in partnership with ANDHealth, selected by the Federal Government to deliver $50m BioMedTech Incubator Program
Read more
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
Read moreVaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)
Read moreComing in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access
Read moreAravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile
Read moreEntact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Read moreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
Read moreCerta Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
Read moreAzura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Read moreOpinion: Taking the leap: transitioning from academia to industry – by Christina Kulis
Read moreBrandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Read moreMedisanté and George Medicines collaborate to bring Internet of Things (IoT) data collection to decentralised Phase III trial of single-pill triple combination candidate to treat hypertension
Read moreGeorge Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial
Read moreVaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration
Read moreGlyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Read moreAustralian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions
Read morePolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
Read moreClinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
Read moreOpinion: Why Australia needs a national biomedical incubator – Simon Wilkins
Read moreGlyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy
Read moreAllay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform
Read moreHope offered to Australians suffering from a rare incurable fibrotic autoimmune disease, as clinical trials on new treatment commence
Read moreENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise
Read moreIndustry-led leadership programme launched to support women into more top science and innovation roles
Read moreAzura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease
Read moreVaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Read moreQUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats
Read moreAustralian Phase II trial commences for potential world-first treatment of viral conjunctivitis
Read morePerth tech takes out Australian start-up competition to join international finals
Read moreAuspherix Awarded Innovate UK Grant to Treat Life-threatening Respiratory Infections
Read moreLevel 9, 31 Queen Street
Melbourne VIC 3000
Phone +61 3 9657 0700
Email: info@brandonbiocatalyst.com
Suite 2.05, 1 York Street
Sydney NSW 2000
Phone +61 2 8227 7080
Email: info@brandonbiocatalyst.com
Ciara Byrne
Caleb Hulme-Moir
